<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04267432</url>
  </required_header>
  <id_info>
    <org_study_id>201703132MSC</org_study_id>
    <nct_id>NCT04267432</nct_id>
  </id_info>
  <brief_title>The Assessment of TCI633 Probiotics on Pain Relief and Functional Improvement in Osteoarthritis</brief_title>
  <official_title>The Assessment of TCI633 Probiotics on Pain Relief and Functional Improvement in Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TCI Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TCI Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess TCI633 probiotics on pain relief and functional improvement in osteoarthritis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind and randomized study. Subjects are informed to consume the samples
      before meals in the morning every day. The clinical and radiological diagnosis of
      osteoarthritis of the knee is evaluated by the doctor. The blood samples and questionnaires
      are collected at every visit of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 28, 2018</start_date>
  <completion_date type="Actual">June 12, 2019</completion_date>
  <primary_completion_date type="Actual">June 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>KL Grade (evaluated by doctor)</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Pain relief and functional improvement in osteoarthritis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WOMACâ„¢ Osteoarthritis Index</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>The questionnaire includes three-part: i) join pain (five questions); ii) joint stiffness (two questions); and, iii) physical functions of joints (seventeen questions). Each question is scored 0-4. Low to high WOMAC scores represent slight to severe OA symptoms. The lower scores mean a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood C-terminal telopeptide of collagen type II (CTX-II) level</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>To measure the level of CTX-II in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood C-reactive protein (CRP) level</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>To measure the level of CRP in blood</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TCI633</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Testing product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 collagen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Known drug for OA</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Blank</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>TCI633</intervention_name>
    <description>Probiotics</description>
    <arm_group_label>TCI633</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Type 2 collagen</intervention_name>
    <description>Positive control group</description>
    <arm_group_label>Type 2 collagen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Osteoarthritis patients with joint pain or discomfort (diagnosed by the physician for
             severe classification of the Kellgren-Lawrence Grade 1-3)

          2. Without heart, liver, kidney, endocrine and other major organic diseases (patient
             return)

        Exclusion criteria

          1. With heart, liver (GOT and GPT values are 3-fold higher than the standard maximum),
             kidney (estimated creatinine clearance less than 25 mL/min), endocrine and other major
             organic diseases (patient return)

          2. People with mental illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ting-Ming Wang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2020</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

